These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19404305)

  • 1. Pharma industry strategic performance: 2008-2013E.
    Goodman M
    Nat Rev Drug Discov; 2009 May; 8(5):348. PubMed ID: 19404305
    [No Abstract]   [Full Text] [Related]  

  • 2. Market watch: sales trends by therapeutic area: 2008-2013E.
    Goodman M
    Nat Rev Drug Discov; 2009 Sep; 8(9):689. PubMed ID: 19721440
    [No Abstract]   [Full Text] [Related]  

  • 3. Why big pharma needs to learn the three 'R's.
    Bradley D
    Nat Rev Drug Discov; 2005 Jun; 4(6):446. PubMed ID: 15959947
    [No Abstract]   [Full Text] [Related]  

  • 4. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building biomanufacturing capacity--the chapter and verse.
    Kamarck ME
    Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies' long revenue stream spurs pharma acquisitions.
    Mitchell P
    Nat Biotechnol; 2007 Nov; 25(11):1194-5. PubMed ID: 17989656
    [No Abstract]   [Full Text] [Related]  

  • 7. Break with tradition.
    Jayaraman KS
    Nature; 2006 Jul; 442(7101):342-3. PubMed ID: 16871181
    [No Abstract]   [Full Text] [Related]  

  • 8. The quiet revolution: outsourcing in pharma.
    Crossley R
    Drug Discov Today; 2004 Aug; 9(16):694. PubMed ID: 15341780
    [No Abstract]   [Full Text] [Related]  

  • 9. Biopharma in Piedmont, Italy.
    Sakariassen KS
    Nat Rev Drug Discov; 2005 Jun; 4(6):519. PubMed ID: 15959953
    [No Abstract]   [Full Text] [Related]  

  • 10. Missed opportunities in pharma?
    Owens J
    Nat Rev Drug Discov; 2004 Oct; 3(10):893. PubMed ID: 15497248
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharma pursues novel models for academic collaboration.
    Hughes B
    Nat Rev Drug Discov; 2008 Aug; 7(8):631-2. PubMed ID: 18670424
    [No Abstract]   [Full Text] [Related]  

  • 12. Big pharma slims down to bolster productivity.
    Owens J
    Nat Rev Drug Discov; 2007 Mar; 6(3):173-4. PubMed ID: 17396286
    [No Abstract]   [Full Text] [Related]  

  • 13. RNAi momentum fizzles as pharma shifts priorities.
    Schmidt C
    Nat Biotechnol; 2011 Feb; 29(2):93-4. PubMed ID: 21301418
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharma consolidates its grip on post-antibody landscape.
    Sheridan C
    Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
    [No Abstract]   [Full Text] [Related]  

  • 15. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niche drugs aren't a cheap alternative to blockbusters.
    Tracey WR
    Nature; 2007 Feb; 445(7130):818. PubMed ID: 17314952
    [No Abstract]   [Full Text] [Related]  

  • 17. The farmyard drug store.
    Nature; 2006 Sep; 443(7107):16-7. PubMed ID: 16957702
    [No Abstract]   [Full Text] [Related]  

  • 18. Little biotech on the prairie.
    Wolfson W
    Chem Biol; 2007 Sep; 14(9):969-71. PubMed ID: 17884626
    [No Abstract]   [Full Text] [Related]  

  • 19. Gloomy pharma forecast in Japan downgraded after quake.
    Morgan B
    Nat Med; 2011 May; 17(5):521. PubMed ID: 21546952
    [No Abstract]   [Full Text] [Related]  

  • 20. To make better therapeutics, companies strive to increase the content of results and get them faster.
    Szpir M
    Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.